Clinical Trial Update: Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CAR-T therapy for intermediate and advanced tumors, including melanoma and non-small cell lung cancer, across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Chimeric Antigen Receptor T Lymphocytes (CAR-T cells)

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Melanoma, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN